Last edition
News about "Marketing Authorisation (MA)"
Japan Approves Rituxan for Steroid-Dependent Nephrotic Syndrome in Adults
Rituxan (rituximab) IV 100 mg and 500 mg receives regulatory approval for adult-onset frequently relapsing or steroid-dependent nephrotic syndrome, with phase 3 data showing an 87.4 percent relapse-free rate at week 49.
Marketing Authorisation (MA) | 20/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members